Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 186HER2-positive Breast Cancer 18Neoplasm Metastasis 6Inflammatory Breast Neoplasms 5Triple Negative Breast Neoplasms 4Neoplasms 4Prostatic Neoplasms 3Pathologic Complete Response 3Pancreatic Neoplasms 3HER2-positive Early Breast Cancer 3Endometrial Neoplasms 3Breast Neoplasms, Male 3Anatomic Stage I Breast Cancer AJCC v8 3Stomach Neoplasms 2Ovarian Neoplasms 2Multiple Myeloma 2Locally Advanced Breast Cancer 2Hematologic Neoplasms 2HER2-positive Metastatic Breast Cancer 2Gastrointestinal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Ductal, Breast 2Breast Diseases 2Brain Neoplasms 2Anatomic Stage II Breast Cancer AJCC v8 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Thrombocytosis 1

Interventions

pyrotinib 2Surgical Procedures, Operative 2pertuzumab 1Trastuzumab 1Neoadjuvant Therapy 1Mastectomy 1Leuprolide 1Goserelin 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Cancer Invasive × pertuzumab × Breast × Clear all
NCT04398914 2022-03-31

Pyrotinib, Trastuzumab, Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer

Shanghai Jiao Tong University School of Medicine

Phase 2 Active not recruiting
216 enrolled
Breast

Breast Cancer Invasive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡